GGrantIndex
← Search

TISSUE CULTURE/ MAb CORE

$149,118P30FY2015CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

PROJECT SUMMARY (See instructions): Objective: The Protein Production, Monoclonal Antibody, Tissue Culture Shared Resource (PPSR) supports basic and translational research at UCCC with validated cell lines, preparation of hybridomas, production of monoclonal antibodies, isolation and titering of baculovirus expressing recombinant proteins, and large scale preparation of recombinant proteins and monoclonal antibodies. Services & Technologies: PPSR provides assays pertinent to cancer research, including generation of hybridomas with desired properties to novel antigens, production of monoclonal antibodies, production of recombinant baculovirus that express proteins of interest, large scale cultivation of cells of varying types, and validated tumor cell lines known to be free of contaminants. In FY2010, 74 human tumor cell lines have been validated for use by UCC investigators. The facility has biosafety cabinets, tissue culture incubators, an ELISA plate reader, bioreactors including three GE Wave bioreactors for large scale cultivation of cells, refrigerators, freezers, and liquid nitrogen storage systems for maintaining stocks of cell lines. Consultation & Training: PPSR provides consultation and technical support to help members prepare and isolate hybridomas that produce monoclonal antibodies with the desired properties directed against their proteins of interest. The facility also provides consultation and technical support for preparation, isolation, and production of recombinant baculovirus vectors encoding proteins of interest to support biochemical, molecular, and structural studies by UCCC members, including large volume (0.5 to 10 I) cultures of insect cells producing the protein of interest. Validated tumor cell lines are maintained by the PPSR allowing UCCC investigators to utilize cell lines known to reflect the original tumor cell line, and to be free of contaminating species, in their research. Utilization: PPSR has served 48 UCCC members from all 6 Programs and 3 consortium institutions. The majority of the reagents and cell lines provided by the PPSR support multiple basic and translational projects. Management and Finances: This resource is UCCC-managed. 61% of the operating budget comes from charge backs to UCCC users who represent 76% of the total users. PPSR requests ~$300K CCSG support for 48% of its operating budget. This increase represents the continuation of the cell line validation service currently supported by ARRA funding. Increased funding will continue our ability to meet the needs of the cancer research community to generate and utilize recombinant proteins, monoclonal antibodies, and provide the community with validated tumor cell lines free of contaminants for use in basic and translational research programs.

View original record on NIH RePORTER →